Raymond James Financial Services Advisors Inc. Sells 3,392 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Raymond James Financial Services Advisors Inc. lowered its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 24.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 10,393 shares of the company’s stock after selling 3,392 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in MiMedx Group were worth $91,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of MDXG. DekaBank Deutsche Girozentrale bought a new position in shares of MiMedx Group during the 3rd quarter worth about $38,000. Robeco Institutional Asset Management B.V. bought a new position in shares of MiMedx Group during the 3rd quarter worth about $74,000. M&T Bank Corp bought a new position in shares of MiMedx Group during the 3rd quarter worth about $75,000. E Fund Management Co. Ltd. bought a new position in shares of MiMedx Group during the 3rd quarter worth about $84,000. Finally, Mackenzie Financial Corp bought a new position in shares of MiMedx Group during the 3rd quarter worth about $88,000. Institutional investors own 79.15% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MDXG shares. Mizuho upped their target price on shares of MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Lake Street Capital started coverage on MiMedx Group in a report on Thursday, March 7th. They issued a “buy” rating and a $12.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.25.

MiMedx Group Stock Down 2.9 %

Shares of NASDAQ:MDXG opened at $6.25 on Friday. The stock has a market cap of $917.77 million, a price-to-earnings ratio of 19.52 and a beta of 1.32. The company has a quick ratio of 3.11, a current ratio of 3.57 and a debt-to-equity ratio of 0.34. MiMedx Group, Inc. has a 12-month low of $3.49 and a 12-month high of $9.27. The business’s 50 day moving average is $7.50 and its 200 day moving average is $7.56.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $86.83 million for the quarter, compared to analysts’ expectations of $85.58 million. MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. On average, sell-side analysts forecast that MiMedx Group, Inc. will post 0.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other MiMedx Group news, COO Ricci S. Whitlow sold 15,271 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the transaction, the chief operating officer now owns 401,050 shares of the company’s stock, valued at $3,212,410.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other MiMedx Group news, COO Ricci S. Whitlow sold 15,271 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the transaction, the chief operating officer now owns 401,050 shares of the company’s stock, valued at $3,212,410.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO William Frank Iv Hulse sold 20,381 shares of the business’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the transaction, the chief accounting officer now directly owns 479,959 shares in the company, valued at approximately $3,815,674.05. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,145 shares of company stock valued at $409,378. Insiders own 19.90% of the company’s stock.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.